Surgical oncology

Results of Multicenter Clinical Trial Sponsored by National Marrow Donor Program/Be The Match published in Journal of Clinical Oncology

Retrieved on: 
Wednesday, April 28, 2021
Research, Surgery, Clinical trials, Biotechnology, General Health, University, Health, Science, Education, Oncology, Medical specialties, Branches of biology, Clinical medicine, Stem cells, National Marrow Donor Program, Hematology, Surgical oncology, Transplantation medicine, Center for International Blood and Marrow Transplant Research, Hematopoietic stem cell transplantation, Organ transplantation, Bone marrow

b'The CIBMTR\xc2\xae (Center for International Blood & Marrow Transplant Research\xc2\xae) manuscript, entitled \xe2\x80\x9cA National Marrow Donor Program Sponsored Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide,\xe2\x80\x9d has been published in the Journal of Clinical Oncology .\nThe CIBMTR is a research collaboration between the National Marrow Donor Program\xc2\xae (NMDP)/Be The Match\xc2\xae and the Medical College of Wisconsin (MCW).

Key Points: 
  • b'The CIBMTR\xc2\xae (Center for International Blood & Marrow Transplant Research\xc2\xae) manuscript, entitled \xe2\x80\x9cA National Marrow Donor Program Sponsored Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide,\xe2\x80\x9d has been published in the Journal of Clinical Oncology .\nThe CIBMTR is a research collaboration between the National Marrow Donor Program\xc2\xae (NMDP)/Be The Match\xc2\xae and the Medical College of Wisconsin (MCW).
  • A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin.
  • In the last ten years, faculty received more than $1.5 billion in external support for research, teaching, training and related purposes.
  • This total includes highly competitive research and training awards from the National Institutes of Health (NIH).

Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study

Retrieved on: 
Tuesday, April 20, 2021
Medicine, Clinical medicine, Medical specialties, Abdominal pain, Digestive system surgery, Surgical oncology, Adhesion, Medical terminology, Bowel resection, Gastrointestinal tract disorders

These early data may indicate that LB1148 is reducing the formation of adhesions.

Key Points: 
  • These early data may indicate that LB1148 is reducing the formation of adhesions.
  • The trial evaluated the use of LB1148 for safety and preliminary efficacy in subjects undergoing elective bowel resection.
  • If this efficacy signal continues to be observed in later stage studies, LB11148 may be a beneficial treatment for post-surgical adhesions for patients under these surgeries.
  • Except as required by applicable law, we do not assume any obligation to update any forward-looking statements.\nLeading BioSciences Media Relations Contact:\n'

Novel Nerve Visualization Investigational Fluorophore Receives FDA IND Approval for First-In-Human Trial

Retrieved on: 
Thursday, April 15, 2021
Branches of biology, Neuroscience, Medicine, Surgical oncology, Myelin, Investigational New Drug, Nerve injury, Prostatectomy, Nerve

b'NEW YORK, April 15, 2021 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Illuminare-1, a small molecule, myelin binding agent, for their Investigational New Drug Application (IND).

Key Points: 
  • b'NEW YORK, April 15, 2021 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Illuminare-1, a small molecule, myelin binding agent, for their Investigational New Drug Application (IND).
  • Illuminare-1 is being developed as a surgical adjunct to improve the visualization and delineation of critical nerve structures intra-operatively in real time with the aim of avoiding serious, and potentially permanent, unintended nerve injury.
  • The ultimate goal of surgery is to repair or remove damaged and/or diseased tissue while preserving vital structures, including nerves.
  • "\nThe Phase 1 trial of Illuminare-1 is a dose-escalation study in up to 50 patients undergoing robot-assisted radical prostatectomy.

Global Radiofrequency-Based Devices Market Report 2020-2030: Focus on Generators, Electrodes, Applicators, Probes, Cannulas, Needles, Others

Retrieved on: 
Wednesday, April 14, 2021
Medicine, Interventional radiology, Medical terminology, Radiofrequency ablation, Surgical oncology, Radio spectrum, Radio frequency

One of the predominant image-guided treatments employed in minimally invasive surgical procedures radio frequency ablation (RFA).

Key Points: 
  • One of the predominant image-guided treatments employed in minimally invasive surgical procedures radio frequency ablation (RFA).
  • Why?\nWhat are the similar technologies available in the market?
  • How do the alternative technologies compare and impact global radio frequency-based devices market?\nWhat are the major technological investments happening in the radio frequency-based devices market by the key players?\nWhich is the pricing analysis of the radio frequency-based products and procedures?\nWhich radio frequency-based devices applications segment is growing and contracting, respectively?
  • Why?\nWhat is the current and future market scenario of the global radio frequency-based devices market?\nWhat are the different entities in the supply chain analyses for the radio frequency-based devices market?\n'

Gynesonics Announces Publication of Clinical Study Analysis Demonstrating Effectiveness of the Sonata System in Treating Submucous and Large Symptomatic Uterine Fibroids

Retrieved on: 
Thursday, April 8, 2021
Health, Medical devices, Consumer, Women, Surgery, General Health, Clinical trials, Clinical medicine, Medicine, Neoplasms, Gynaecological neoplasia, Uterine fibroid, Gynecological surgery, Uterine myomectomy, Surgical oncology, Interventional radiology, Heavy menstrual bleeding, Sonata System, Gynesonics

Among 197 women (with 534 treated fibroids), 86% of patients with only submucous fibroids and 81% of women with large fibroids (>5 cm) experienced bleeding reduction within 3 months post-ablation.

Key Points: 
  • Among 197 women (with 534 treated fibroids), 86% of patients with only submucous fibroids and 81% of women with large fibroids (>5 cm) experienced bleeding reduction within 3 months post-ablation.
  • Additional fibroid mapping of large fibroids with magnetic resonance imaging in the FAST-EU trial showed an average volume reduction of 68%.
  • Transcervical fibroid ablation with the Sonata system for treatment of submucous and large uterine fibroids.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference

Retrieved on: 
Thursday, March 25, 2021
Health, General Health, Branches of biology, Biology, Life sciences, Biotechnology, Hematology, Hematopoietic stem cell transplantation, Surgical oncology, Transplantation medicine, Stem cell, Organ transplantation

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, is scheduled to participate in a panel discussion at the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference, being held virtually, on Thursday, April 1st, 2021.

Key Points: 
  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, is scheduled to participate in a panel discussion at the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference, being held virtually, on Thursday, April 1st, 2021.
  • The panel discussion, Key Advances in Solid Organ and Stem Cell Transplants - Expanding the Market and Moving Away from Lifelong Immunosuppression, will take place at 1:00 p.m.
  • A live webcast of the panel discussion can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .
  • Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.

Brendon Stiles, M.D., Named Chief of Thoracic Surgery & Surgical Oncology at Montefiore and Albert Einstein College of Medicine

Retrieved on: 
Friday, March 19, 2021
Medical specialties, Surgery, Clinical medicine, Surgical specialties, Cardiac surgery, Cardiothoracic surgery, Thoracic surgery, Surgical oncology, Raja M. Flores, Jeffrey P. Gold

BRONX, N.Y., March 19, 2021 /PRNewswire/ -- Leading cardiothoracic surgeon and researcher, Brendon Stiles, M.D., has been appointed chief of the division of thoracic surgery & surgical oncology in the department of cardiothoracic and vascular surgery at Montefiore Health System and Albert Einstein College of Medicine.

Key Points: 
  • BRONX, N.Y., March 19, 2021 /PRNewswire/ -- Leading cardiothoracic surgeon and researcher, Brendon Stiles, M.D., has been appointed chief of the division of thoracic surgery & surgical oncology in the department of cardiothoracic and vascular surgery at Montefiore Health System and Albert Einstein College of Medicine.
  • Additionally, Dr. Stiles is serving as the associate director of surgical services for the surgical oncology line at the National Cancer Institute-designated Albert Einstein Cancer Center.
  • "Dr. Stiles' expertise in thoracic surgical oncology expands the clinical options we can provide our patients with lung disease.
  • Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation.

Targeted Oncology™ Adds Two New Premier Oncology Association Partners to Its Strategic Alliance Partnership Program

Retrieved on: 
Tuesday, March 16, 2021
Research, Nursing, Surgery, Other Health, Radiology, Health, Other Science, Science, Oncology, Medical specialties, Oncology, Medicine, Health care, Surgical oncology, Musculoskeletal Tumor Surgery

We are pleased to see continuing collaboration between such prominent organizations in the field of oncology through the Strategic Alliance Partnership (SAP) program, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of Targeted Oncology.

Key Points: 
  • We are pleased to see continuing collaboration between such prominent organizations in the field of oncology through the Strategic Alliance Partnership (SAP) program, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of Targeted Oncology.
  • Each partner in the SAP program has the same common goal: improving the quality of life for all patients.
  • Virginia Cancer Specialists offers medical oncology, radiation oncology, musculoskeletal tumor surgery, breast surgery, thoracic surgery, genetic counseling, palliative care, oncology nurse navigators, oncology infusion nurses, oncology pharmacists, social workers, dietitians and laboratory technicians.
  • TargetedOnc.com , the website for Targeted Oncology, provides practicing oncologists with the latest news and insights on next-generation therapeutics and their molecular targets.

Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting

Retrieved on: 
Monday, March 15, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Medical specialties, Clinical medicine, Medicine, Transplantation medicine, Stem cells, Hematology, Surgical oncology, Hematopoietic stem cell transplantation, Lymphology, Graft-versus-host disease, Chemotherapy, Immunosuppression

MGTA-145 plus plerixafor rapidly mobilized large numbers of HSCs and showed durable engraftment, successful gene-modification and immunosuppressive properties by reducing Graft-versus-Host disease (GvHD) in preclinical models.

Key Points: 
  • MGTA-145 plus plerixafor rapidly mobilized large numbers of HSCs and showed durable engraftment, successful gene-modification and immunosuppressive properties by reducing Graft-versus-Host disease (GvHD) in preclinical models.
  • Magentas targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to stem cell transplant or gene therapy.
  • The conditioning ADCs have the potential to reduce or eliminate the need for high dose or high intensity chemotherapy-based conditioning regimens.
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials

Retrieved on: 
Friday, March 12, 2021
Branches of biology, Medical specialties, Clinical medicine, Transplantation medicine, Stem cells, Biotechnology, Cell biology, Hematopoietic stem cell transplantation, Surgical oncology, Organ transplantation, Sickle cell disease

NEW YORK, March 12, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the Company"), the world leader in Veto Cell based immunotherapy technologies that can safely facilitate mismatched donor stem cell transplants, e.g.

Key Points: 
  • NEW YORK, March 12, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the Company"), the world leader in Veto Cell based immunotherapy technologies that can safely facilitate mismatched donor stem cell transplants, e.g.
  • "Sickle cell disease diminishes the quality of life and lowers the life expectancy of approximately 100,000 people in the United States alone," said Dennis Brown, Chairman of Cell Source.
  • Our Veto Cell based protocol could overcome the lack of suitable donors, treatment toxicities, and graft-related challenges.
  • Cell Source's Veto Cell technologies are also being developed to facilitate safe, mismatched organ transplants (e.g., kidney and liver) without the need for life-long immune system suppression.